Asymchem Laboratories Breaks Ground For Jilin Production Base
This article was originally published in PharmAsia News
Executive Summary
Asymchem Laboratories, a leading pharmaceutical CRO in China, recently started constructing its new 220,000-square-meter production facility in Jilin Dunhua Economic Development Zone. With total investment of 240 million yuan, Asymchem Laboratories (Jilin) will house FDA cGMP-compliant clean manufacturing space, supply stores and an advanced international-standard EHS control center that produces high-level active pharmaceutical ingredients, pharmaceutical intermediates and relevant basic raw materials. The project's first phase is expected to be fully operational in early 2009 with an annual output of over 30 tons to achieve production value of 1.5 billion yuan within three years. (Click here for more - Chinese Language)
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.